Amiodarone
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Amiodarone and local guidelines before prescribing.
Mechanism
Class III antiarrhythmic prolonging repolarisation; also blocks sodium and calcium channels and beta receptors.
Uses
VT/VF, AF and flutter rhythm control, supraventricular tachycardias.
Dosing
Quick reference (Makindo topics site)
| Main use | Adult dose | Key pearl / caution |
|---|---|---|
| VT / VF | 300 mg IV in arrest; 150 mg over 10 min for stable VT | Monitor QT, BP, bradycardia. |
Source: Makindo topics, Emergency Drugs Collection (topic 1479). Editorial draft, not clinically signed off; doses are as written there. Check BNF and local policy before prescribing.
- Shockable rhythms — VF and pulseless VT — defibrillate, CPR for 2 minutes; adrenaline 1 mg and amiodarone 300 mg after the 3rd shock.
Cardiology: Presentations - Cardiac arrest - VF/pulseless VT | CPR; shock; 2 minutes CPR between shocks; adrenaline 1 mg and amiodarone 300 mg after the 3rd shock
Cardiology: Cardiology Emergencies - Unstable tachycardia | Synchronised DC cardioversion (up to 3 attempts, under sedation); then amiodarone 300 mg IV
Cardiology: Cardiology Emergencies - Immediate defibrillation and ALS: adrenaline 1 mg and amiodarone 300 mg after the third shock.
Cardiology: Ischaemic Heart Disease (ACS) › 1.26 Arrhythmias After MI
4 more dose entries from the chapters
- Pulse but adverse features (shock, syncope, ischaemia, heart failure): synchronised DC cardioversion (up to 3 attempts), then amiodarone 300 mg IV over 10–20 minutes.
Cardiology: Ischaemic Heart Disease (ACS) › 1.26 Arrhythmias After MI - Stable monomorphic VT: RCUK March 2026 favours synchronised cardioversion for most; if sedation risks are high, expert-guided procainamide 10–15 mg/kg IV over 20 min (maximum 1 g), or amiodarone 300 mg IV over 10–60 min followed by 900 mg over 24 h when procainamide unsuitable.
Cardiology: Cardiac Arrhythmias › 5.21 Monomorphic Ventricular Tachycardia - Amiodarone: 300 mg IV/IO after three shocks; 150 mg after five shocks for recurrent/persistent VF/pVT. Lidocaine is an alternative where specified.
Cardiology: Cardiac Arrhythmias › 5.23 Ventricular Fibrillation and Pulseless VT - Amiodarone | Arrhythmia: 200 mg three times daily for 1 week, twice daily for 1 week, then 200 mg daily; monitor TFT, LFT, lungs, eyes and skin.
Cardiology: Cardiomyopathies › 3.54 Common Adult Drugs and Doses
Side effects
Thyroid dysfunction, pulmonary fibrosis, hepatitis, photosensitivity, corneal deposits, bradycardia, QT prolongation, neuropathy.
Interactions
Raises levels of digoxin, warfarin and simvastatin; avoid other QT-prolonging drugs; additive bradycardia with beta-blockers and verapamil.
Contraindications and cautions
Thyroid dysfunction, iodine hypersensitivity, bradycardia, heart block, QT prolongation
Monitoring
Baseline and 6-monthly TFT and LFT, annual CXR and eyes if symptoms, ECG
Pregnancy and breastfeeding
Avoid unless essential (neonatal thyroid effects)
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive; very long half-life
Special advice
Baseline then regular TFT, LFT, chest X-ray, ECG; sun protection; central IV line for infusions; very long half-life.
More from the textbook: uses, cautions and other points
- Phase 3 - repolarisation: potassium channels (e.g. hERG) let potassium out - blocked by class III drugs (amiodarone, sotalol) and many QT-prolonging drugs.
Cardiology: Anatomy Physiology and Pharmacology - Conduction block - fibrosis or ischaemia of the conduction system (heart block), drugs (beta-blockers, calcium channel blockers, digoxin, amiodarone), hyperkalaemia.
Cardiology: Anatomy Physiology and Pharmacology - Unstable tachyarrhythmia (shock, syncope, myocardial ischaemia, heart failure) — synchronised DC cardioversion (up to 3 attempts), then amiodarone.
Cardiology: Presentations - Stable tachyarrhythmia — narrow regular (vagal manoeuvres, adenosine), narrow irregular (AF — rate control), broad regular (VT — amiodarone).
Cardiology: Presentations - Drugs: Beta-blockers, rate-limiting calcium channel blockers (verapamil, diltiazem), digoxin, amiodarone, ivabradine.
Cardiology: Cardiology Emergencies - Amiodarone in critically ill patients or acute heart failure where other drugs are unsuitable.
Cardiology: Cardiology Emergencies
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (15 mentions)
- Cardiology: Presentations (5 mentions)
- Cardiology: Cardiology Emergencies (17 mentions)
- Cardiology: Ischaemic Heart Disease (ACS) (4 mentions)
- Cardiology: Cardiac Arrhythmias (14 mentions)
- Cardiology: Cardiomyopathies (9 mentions)
- Respiratory: Anatomy, Physiology and Pharmacology (2 mentions)
- Respiratory: Interstitial Lung Disease (4 mentions)
- Respiratory: Lung Cancer (1 mention)
- Endocrine: Anatomy Physiology and Pharmacology (3 mentions)
- Endocrinology: Thyroid disease (18 mentions)
- Gastroenterology: Anatomy Physiology Pharmacology (4 mentions)
- Gastroenterology: Liver disease (3 mentions)
- Neurology: Anatomy, Physiology and Pharmacology (3 mentions)
- Neurology: Movement Disorders (1 mention)
- Neurology: Neuromuscular disease (2 mentions)
- Renal: Anatomy, Physiology and Pharmacology (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (3 mentions)
- Haematology: Haemostasis and Thrombosis (1 mention)
- Obstetrics (1 mention)
- Obstetrics: Medical Problems (1 mention)
- Gynaecology: Sexual health (1 mention)
- Dermatology: Skin lesions and skin cancer (1 mention)
- Dermatology: Urticaria, drug reactions, blistering, ulcers and emergencies (3 mentions)
- Ophthalmology: Anatomy Physiology and Pharmacology (2 mentions)